Clinical trial NCT01049360: Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo
Official title: Efficacy and Safety Study of Two Fixed-Dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate, and Placebo All Administered Twice Daily (BID) to Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: Chronic Obstructive Pulmonary Disease
COPD
Chronic Bronchitis
Emphysema
Airflow Obstruction, Chronic
Chronic Airflow Obstruction
Chronic Obstructive Airway Disease
Chronic Obstructive Lung Disease
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2010-01-14
Enrollment: 128
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of this multicenter, randomized, double-blind, placebo-controlled, 4-period, incomplete-block crossover, dose-ranging study comparing 2 fixed dose combinations (FDCs) of aclidinium bromide with formoterol fumarate or with placebo, aclidinium bromide and formoterol fumarate, all administered twice a day (BID) in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD) beginning with a 2-week run-in period and with a 7-10 day washout each between treatment period.


Eligibility criteria: Inclusion Criteria:

* Understand the study procedures and be willing to participate in the study as indicated by signing the ICF and HIPAA form
* Be male or female aged 40 to 80 years, inclusive
* Have a diagnosis of stable, moderate to severe COPD (stages II and III) as defined by guidelines of the Global Initiative for Chronic Obstructive Lung Disease (2008)
* Be a current or former cigarette smoker with a smoking history of at least 10 pack-years
* Have post-albuterol/salbutamol FEV1 values ≥ 30% and \< 80% of the predicted value. FEV1 will be measured at the Screening Visit (Visit 1) between 10 and 15 minutes after inhalation of albuterol/salbutamol.
* Have post-albuterol/salbutamol FEV1/FVC values \< 70% (ie, 100 × post- albuterol/salbutamol FEV1/FVC \< 70%).
* If female, be at least 1 year postmenopausal or surgically sterile (defined as having a hysterectomy or tubal ligation). Women of childbearing potential must have a negative serum β-human chorionic gonadotropin pregnancy test at screening
* Be in good stable health (as judged by the Investigator) other than the COPD, based on medical history, physical examination, ECG, spirometry, and clinical laboratory data evaluations
* Have COPD symptoms and FEV1 values at the time of randomization that are stable compared with those at Screening (Visit 1), according to the Investigator's medical judgment

Exclusion Criteria:

* Have been hospitalized for an acute COPD exacerbation within 3 months before screening
* Have any respiratory tract infection (including the upper respiratory tract) or signs of a COPD exacerbation or respiratory infection in the 6 weeks before Screening (Visit 1).
* Have any clinically significant respiratory conditions other than COPD
* Have a history or presence of asthma verified from medical records
* Have used theophylline (including long-acting theophylline) within the previous 3 months before study entry
* Have Stage II hypertension, defined as systolic pressure of 160 and above, and diastolic pressure of 100 and above
* Chronic use of oxygen therapy ≥ 15 hours a day
* Have a history, current diagnosis, or presence of exercise-induced bronchospasm
* Have a body mass index ≥ 40 kg/m2
* Have participated in an pulmonary rehabilitation program within the previous 3 months
* Have clinically significant cardiovascular conditions
* Have uncontrolled infection resulting from human immunodeficiency virus and/or active hepatitis
* Have symptomatic prostatic hypertrophy and/or bladder neck obstruction.
* Have narrow-angle glaucoma
* Have a history of hypersensitivity reaction (including report of paradoxical bronchospasm) to inhaled anticholinergics (including aclidinium bromide), β2 adrenergic agonists, or any other inhaled medication or any component thereof
* Have a QTcB, as indicated in the centralized reading report, above 470 msec in the resting ECGs performed at Screening (Visit 1) and/or patients who are using medications that may prolong the QT interval
* Have clinically relevant abnormalities in the results of clinical laboratory tests, in ECG parameters other than QTc, in results of the physical examination,
* Have any concurrent medical condition that, in the judgment of the Investigator, might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the patient's well-being
* Do not maintain regular day/night, waking/sleeping cycles (eg, patients with history of sleep apnea syndrome or any disease related with sleep disturbances such as restless legs syndrome or somnambulism)

Primary outcomes:
measure: Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12)
timeFrame: 0 to 12 hours post-dose on Day 14
Secondary outcomes:
measure: Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)
timeFrame: Day 14
measure: Change From Baseline in Morning Peak Forced Expiratory Volume in One Second (FEV1)
timeFrame: Day 14
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Forest Investigative Site 0909
state: Arizona
city: Pheonix
country: United States
facility: Forest Investigative Site 2050
state: Arizona
city: Rancho Mirage
country: United States
facility: Forest Investigative Site 2029
state: California
city: Stockton
country: United States
facility: Forest Investigative Site 1084
state: California
city: Wheat Ridge
country: United States
facility: Forest Investigative Site 2045
state: Colorado
city: Clearwater
country: United States
facility: Forest Investigative Site 1152
state: Florida
city: Tampa
country: United States
facility: Forest Investigative Site 2053
state: Florida
city: Tampa
country: United States
facility: Forest Investigative Site 2047
state: Florida
city: N. Dartmouth
country: United States
facility: Forest Investigative Site 1431
state: Massachusetts
city: Summit
country: United States
facility: Forest Investigative Site 2084
state: New Jersey
city: Elmira
country: United States
facility: Forest Investigative Site 1119
state: New York
city: Elizabeth city
country: United States
facility: Forest Investigative Site 2035
state: North Carolina
city: Raleigh
country: United States
facility: Forest Investigative Site 1153
state: North Carolina
city: Cincinnati
country: United States
facility: Forest Investigative Site 2028
state: Ohio
city: Medford
country: United States
facility: Forest Investigative Site 2043
state: Oregon
city: Portland
country: United States
facility: Forest Investigative Site 1106
state: Oregon
city: E. Providence
country: United States
facility: Forest Investigative Site 1089
state: Rhode Island
city: Spartanburg
country: United States
facility: Forest Investigative Site 1121
state: South Carolina
city: San Antonio
country: United States
facility: Forest Investigative Site 1498
state: Texas
city: Waco
country: United States
facility: Forest Investigative Site 1129
state: Texas
Study officials:
affiliation: AstraZeneca
name: Esther Garcia, MD
role: STUDY_DIRECTOR
References: